Rasagiline
- Generic Name
- Rasagiline
- Brand Names
- Azilect, Rasagiline Mylan, Rasagiline ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N
- CAS Number
- 136236-51-6
- Unique Ingredient Identifier
- 003N66TS6T
Overview
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Background
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Associated Conditions
- Parkinson's Disease (PD)
Clinical Trials
FDA Approved Products
Rasagiline
Manufacturer:Teva Pharmaceuticals USA, Inc.
Route:ORAL
Strength:0.5 mg in 1 1
Approved: 2023/08/24
NDC:0093-3060
Azilect
Manufacturer:Teva Neuroscience, Inc.
Route:ORAL
Strength:1 mg in 1 1
Approved: 2023/08/22
NDC:68546-229
Rasagiline
Manufacturer:Alvogen, Inc.
Route:ORAL
Strength:1 mg in 1 1
Approved: 2019/03/27
NDC:47781-690
Azilect
Manufacturer:Teva Neuroscience, Inc.
Route:ORAL
Strength:0.5 mg in 1 1
Approved: 2023/08/22
NDC:68546-142
Azilect
Manufacturer:Physicians Total Care, Inc.
Route:ORAL
Strength:1 mg in 1 1
Approved: 2010/12/07
NDC:54868-6206
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath